Themis Medicare reported net Sales of Rs.48.49 crore for the Jun-20 quarter, a fall of 5.54% on a YOY basis compared to the corresponding quarter last year. Net Profit for the Jun-20 quarter was up by nearly 50% at Rs.7.75 crore on the back of better cost management.
Themis reported EBITDA at Rs.12.66 crore for the Jun-20 quarter, sharply up by 66% compared to Rs. 7.61 crore in the Jun-19 quarter. The stock also saw a sharp rise in EPS to Rs.8.44. The stock has more than doubled in price over the last one year on pharma push.
Themis Medicare reported net Sales of Rs.48.49 crore for the Jun-20 quarter, a fall of 5.54% on a YOY basis compared to the corresponding quarter last year. Net Profit for the Jun-20 quarter was up by nearly 50% at Rs.7.75 crore on the back of better cost management.
Themis reported EBITDA at Rs.12.66 crore for the Jun-20 quarter, sharply up by 66% compared to Rs. 7.61 crore in the Jun-19 quarter. The stock also saw a sharp rise in EPS to Rs.8.44. The stock has more than doubled in price over the last one year on pharma push.